Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Open-Label, Multicenter Study to Assess the Safety and Anti-Tumor Efficacy of AZD4205 in Participants With Peripheral T Cell Lymphoma Who Have Responded After First-Line Standard Therapy

NCT06511869 is registered in ClinicalTrials.gov with Dizal Pharmaceuticals as lead sponsor.

NCT NCT06511869
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06511869 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Open-Label, Multicenter Study to Assess the Safety and Anti-Tumor Efficacy of AZD4205 in Participants With Peripheral T Cell Lymphoma Who Have Responded After First-Line Standard Therapy
Lead sponsor
Dizal Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
March 17, 2022
Completion date
March 31, 2025
Enrollment
48 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

peripheral t-cell lymphoma